Engineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut
Anti-inflammatory treatments for gastrointestinal diseases can often have detrimental side effects. Here the authors engineer E. coli Nissle 1917 to create a fibrous matrix that has a protective effect in DSS-induced colitis mice.
Guardado en:
Autores principales: | Pichet Praveschotinunt, Anna M. Duraj-Thatte, Ilia Gelfat, Franziska Bahl, David B. Chou, Neel S. Joshi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/da22cd1382ed4f4c88ee9a65f788efef |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Modulating bacterial and gut mucosal interactions with engineered biofilm matrix proteins
por: Anna M. Duraj-Thatte, et al.
Publicado: (2018) -
Author Correction: Modulating bacterial and gut mucosal interactions with engineered biofilm matrix proteins
por: Anna M. Duraj-Thatte, et al.
Publicado: (2021) -
Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity.
por: Sya N Ukena, et al.
Publicado: (2007) -
Identification of an analgesic lipopeptide produced by the probiotic Escherichia coli strain Nissle 1917
por: Teresa Pérez-Berezo, et al.
Publicado: (2017) -
E. coli Nissle 1917 modulates host glucose metabolism without directly acting on glucose
por: Theodore A. Chavkin, et al.
Publicado: (2021)